Promising data for advanced melanoma patients

Promising data for advanced melanoma patients

9 October 2019

Melanoma Institute Australia (MIA) has presented promising data regarding progression-free survival rates for advanced melanoma patients at the European Society for Medical Oncology (ESMO) 2019 Congress in Barcelona.

Follow-up data from the ground-breaking ABC (Anti-PD1 Brain Collaboration) trial was presented by MIA Co-Medical Director Professor Georgina Long.  This trial is a phase II randomised trial involving melanoma patients with untreated brain metastases receiving either a combination of nivolumab and ipilimumab or nivolumab alone –In patients who received the combination therapy, 43% had no disease progression in their brain after three years. The 3-year rate for no progression of metastases in the brain increased to 48% if patients had no prior therapy. These 3-year rates indicate the ongoing durability of intracranial response from immunotherapy, and that the response is likely to continue long-term for almost half of all patients.

The overall survival rate at 3 years on the combination treatment was 49%, on single therapy was 42%, and a final cohort – those patients who would usually have been excluded from clinical trials because of the severity of their brain metastases – was 19%, which is a significant increase in life expectancy for these patients.

Five-year survival rates from the longest-running phase III trial of combination immunotherapy in melanoma patients were also presented at ESMO. The overall survival for those patients on combination ipilimumab and nivolumab was 52%, with 36% of patients progression-free.

Also on display at ESMO were four posters from our researchers. Post-doctoral researcher Dr. Ines da Silva presented our findings on the overall survival of melanoma patients based on the pattern of their metastases, and was awarded the best poster presentation at ESMO. She found that patients with brain metastases and liver metastases lived for shorter periods than patients without melanoma in these sites. She also found that different metastatic sites were asociated with different patterns of further metastasis, indicating that patterns of metastasis may be another helpful factor in determining prognosis.

Medical oncology Fellow Dr. Adriana Hepner presented data on the efficacy and safety of immunotherapy treatment after a patient has become resistant to combination immunotherapy. She found that giving patients immunotherapy again after they have already become resistant benefited a small subset of patients, although patients may have a recurrence of previous toxicities. This poster highlighted the need for further research into new and different treatments for these patients.

Medical oncologist and MIA PhD student Dr. Kazi Nahar's, presented her work on the characteristics of one of the major immune-related toxicities caused by immunotherapy treatment – colitis, or inflammation of the inner lining of the colon. She found that combination immunotherapy - while being highly effective for many melanoma patients - was more likely to cause earlier onset and more severe colitis in melanoma patients that also seems to be more resistant to steroid treatment.

Finally, PhD student Hansol Lee presented a poster that discussed the role of a type of immune cell called macrophages, on response to combination immunotherapy. He found that patients who responded to treatment had more macrophages within their tumour before they began treatment, and a higher amount of a particular subset of macrophages is associated with a significantly better overall response and progression-free survival rate.

A message to all Australians from melanoma patient Stuart Taylor
16 Dec 2020

A message to all Australians from melanoma patient Stuart Taylor

Stuart has advanced melanoma which is not responding to treatment. He has shared his story on ABC's 7:30 in the hope that others can escape the same fate. 

Tags: melanoma
Olivia Vivian nominates MIA as Charity Partner on Channel 9's Celebrity Apprentice.
02 Dec 2020

Olivia Vivian nominates MIA as Charity Partner on Channel 9's Celebrity Apprentice.

A Ninja Warrior legend and Olympic gymnast, Olivia knows first hand the devastating impact of melanoma.

Tags: melanoma
It's 'Game On Mole' this summer!
01 Dec 2020

It's 'Game On Mole' this summer!

All Australians are urged to join the fight against melanoma this summer. 

Tags: melanoma
Prof Richard Scolyer named Outstanding Cancer Researcher of the Year  
27 Nov 2020

Prof Richard Scolyer named Outstanding Cancer Researcher of the Year  

The ground-breaking work of MIA's Co-Medical Director Prof Richard Scolyer has been recognised with NSW’s highest accolade for cancer research. 

Tags: melanoma
Dr James Wilmott wins 2020 Wildfire Highly Cited Publication Award
24 Nov 2020

Dr James Wilmott wins 2020 Wildfire Highly Cited Publication Award

A landmark study led by MIA's Dr Willmott is making a difference to melanoma treatment around the globe.

Tags: melanoma
MIA researchers feature on prestigious Highly Cited Researchers 2020 List
18 Nov 2020

MIA researchers feature on prestigious Highly Cited Researchers 2020 List

The highly anticipated annual list is the “who’s who” of the scientific elite from across the globe.

Tags: melanoma
Game On Mole is back this summer!
13 Nov 2020

Game On Mole is back this summer!

The uniquely Aussie awareness campaign ‘Game On Mole’ is back for its second year – with a new look but same important message.

Tags: melanoma
RCPA recognition for Professor Richard Scolyer.
12 Nov 2020

RCPA recognition for Professor Richard Scolyer.

Professor Richard Scolyer receives The Royal College of Pathologists of Australasia Distinguished Fellow Award.

Tags: melanoma
Professor Georgina Long hands on baton of SMR Presidency
31 Oct 2020

Professor Georgina Long hands on baton of SMR Presidency

Professor Long cites as a highlight of her 2-year Presidency, the phenomenal research output by SMR members who have continued to lead the cancer field despite the impact of COVID-19.

Tags: melanoma
City2Surf 2020
11 Sep 2020

City2Surf 2020

Join in the fun of the virtual event, and together we can run over melanoma!

Tags: melanoma
Top melanoma experts from MIA
10 Sep 2020

Top melanoma experts at MIA

Melanoma Institute Australia features prominently in the latest ‘Expertise in Melanoma’ world rankings, released by Expertscape.

Tags: melanoma
Top melanoma experts from MIA
10 Sep 2020

Top melanoma experts from MIA

Melanoma Institute Australia features prominently in the latest ‘Expertise in Melanoma’ world rankings, released by Expertscape.

Tags: melanoma
Melanoma Supportive Care Needs research study. 
03 Sep 2020

Melanoma Supportive Care Needs research study. 

Participate in our online survey and help us understand the support needs of melanoma patients and carers.

Tags: melanoma
New data reveals long-term benefit of adjuvant therapy for Stage III melanoma.
03 Sep 2020

Research reveals long-term benefit of adjuvant therapy for Stage III melanoma

Updated results published in the New England Journal of Medicine.
Tags: melanoma
New data reveals long-term benefit of adjuvant therapy for Stage III melanoma.
03 Sep 2020

New data reveals long-term benefit of adjuvant therapy for Stage III melanoma.

Updated results published in the New England Journal of Medicine.
Tags: melanoma
New online melanoma risk calculators critical to saving lives
28 Aug 2020

New online melanoma risk calculators critical to saving lives

Clinicians and their patients now have access to three online risk calculators developed by researchers at Melanoma Institute Australia.

Tags: melanoma
Professor Richard Scolyer receives University of Sydney Alumni Award.
24 Aug 2020

Professor Richard Scolyer receives University of Sydney Alumni Award.

MIA's Co-Medical Director Professor Richard Scolyer has received The University of Sydney Alumni Award for International Achievement.

Tags: melanoma
Uniting together despite the distance
21 Aug 2020

Uniting together despite the distance

More than 120 MIA clinicians, researchers and staff came together online to share research highlights.

Tags: melanoma
Professor Richard Scolyer recognised in The Pathologist's 2020 Power List.
03 Aug 2020

Professor Richard Scolyer recognised in The Pathologist's 2020 Power List.

For the 2nd consecutive year, MIA's Co-Medical Director Professor Richard Scolyer has been selected in the top 100 best, brightest, and most powerful advocates of pathology by The Pathologist.

Tags: melanoma
Important Update: Masks required at Poche Centre
24 Jul 2020

Important Update: Masks required at Poche Centre

As of Monday 27th July all patients and carers/family members coming into The Poche Centre will be required to bring their own mask. 

Tags: melanoma